EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 141 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.34 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $887,000 | -26.8% | 16,000 | -33.3% | 0.01% | -31.2% |
| Q1 2019 | $1,212,000 | +25.3% | 24,000 | 0.0% | 0.02% | +6.7% |
| Q4 2018 | $967,000 | -41.9% | 24,000 | 0.0% | 0.02% | -31.8% |
| Q3 2018 | $1,664,000 | -8.4% | 24,000 | 0.0% | 0.02% | -24.1% |
| Q2 2018 | $1,816,000 | +43.6% | 24,000 | 0.0% | 0.03% | +31.8% |
| Q1 2018 | $1,265,000 | -1.3% | 24,000 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $1,282,000 | -63.6% | 24,000 | -59.3% | 0.02% | -63.9% |
| Q3 2017 | $3,519,000 | -7.1% | 59,000 | +22.9% | 0.06% | -14.1% |
| Q2 2017 | $3,787,000 | -4.9% | 48,000 | 0.0% | 0.07% | -7.8% |
| Q1 2017 | $3,981,000 | -19.1% | 48,000 | -22.6% | 0.08% | -31.9% |
| Q4 2016 | $4,919,000 | +4.9% | 62,000 | -7.5% | 0.11% | 0.0% |
| Q3 2016 | $4,690,000 | +119.8% | 67,000 | +21.8% | 0.11% | +105.5% |
| Q2 2016 | $2,134,000 | -7.9% | 55,000 | -4.3% | 0.06% | -5.2% |
| Q1 2016 | $2,316,000 | – | 57,500 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 400,000 | $5,732,000 | 1.52% |
| Park West Asset Management LLC | 426,900 | $6,117,000 | 0.80% |
| WALL STREET ASSOCIATES | 200,000 | $2,866,000 | 0.25% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 284,653 | $4,079,000 | 0.16% |
| FARALLON CAPITAL MANAGEMENT LLC | 100,000 | $1,433,000 | 0.02% |
| NEXT Financial Group, Inc | 2,500 | $26,000 | 0.01% |
| PIPER SANDLER & CO. | 1,277 | $18,000 | 0.01% |
| Ground Swell Capital, LLC | 400 | $6,000 | 0.01% |
| PARADIGM ASSET MANAGEMENT CO LLC | 6,300 | $90,279,000 | 0.01% |
| Paloma Partners Management Co | 14,363 | $206,000 | 0.01% |